IRMD
IRadimed Corporation · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | -3 | 5.35M | $511.40M | +6 | −8 |
| Q1 2026 | 88 | +3 | 5.07M | $488.33M | +6 | −3 |
| Q4 2025 | 85 | 0 | 4.93M | $479.86M | +1 | −1 |
| Q3 2025 | 16 | +1 | 3.09M | $220.20M | +1 | n/a |
| Q2 2025 | 12 | +2 | 2.63M | $157.45M | +2 | n/a |
| Q1 2025 | 7 | -1 | 1.04M | $54.42M | n/a | −1 |
| Q4 2024 | 8 | +1 | 1.01M | $55.33M | +1 | n/a |
| Q3 2024 | 6 | -3 | 875.49K | $44.03M | n/a | −3 |
| Q2 2024 | 9 | n/a | 935.05K | $41.09M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 560.21K | n/a | $24.62M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 190.46K | n/a | $8.37M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 83.05K | n/a | $3.65M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 39.90K | n/a | $1.75M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 17.75K | n/a | $779,935 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passive) | 16.50K | n/a | $725,010 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 10.53K | n/a | $462,731 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 8.44K | n/a | $370,680 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 9 | D. E. Shaw & Co. ✦ | 8.20K | n/a | $360,396 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 225 holders, 7.61M shares, $667.38M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 1.01K sh · $87,650
Director · 405 sh · $34,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology